MURA Mural Bio: Net Margin

Mural Oncology - graphic logo of issuer MURA

Mural Oncology plc (MURA) focuses on the procurement of treatments for melanoma and kidney cancer, yet faces a lack of profitable products and stable cash flow. The aggregate net margin illustrates this balance, where 0.00 is the current value of the metric. This trend reflects the development of proprietary protein platforms, which create a robust patent barrier to protect the company's market positions.

MURA: Mural Oncology Net Profit Rate 02/21/2024 - 12/20/2025

Comprehensive metric breakdowns and analytics for muraloncology.com (MURA)

- share price and expert price forecast:
- company stock capitalization data:
Basic company analysis:Mural Oncology plc
Manufactured product of Mural Oncology plc

Investors must evaluate internal business efficiency to determine the asset's fundamental value. Net profitability measures the portion of profit remaining after covering all operating and financial expenses. Analyzing current sales margins helps identify the stability of cash flows. For Mural Oncology (MURA), this indicator reflects the cost of scaling the nemvalekin platform. Capital management efficiency is critical here during expansion into the precision cancer therapy segment.

Analysis of competing companies

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|Net Profit Rate DCTH (Delcath Corp)|YMAB: Net Sales Margin|AURA - Company Sales Margin|CADL (Candel Therapeutics Inc.) - Net Sales Margin|Net Return on Sales ARAY (Accuray)|Return on Sales by Net Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Net Margin|Net Margin Citius Oncology, Inc. CTOR|HURA - Return on Sales by Net Profit|protaratx.com - Net Sales Margin|FATE - Net Sales Margin|WHWK: Net Sales Margin|TScan Therapeutics (TCRX) - Net Sales Margin|Net Margin Champions Oncology|Net Margin XBIT|Net Sales Margin CVM|Return on Sales by Net Profit OS Therapies Inc. OSTX|Net Margin Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Net Margin|ANL - Net Margin|Net Margin verupharma.com|TPST: Net Sales Margin|XLO - Company Sales Margin|Net Margin Renovaro|Kairos Pharma Ltd - Net Profit Margin|Net Sales Margin OKUR|CytoMed Therapeutics Limited (GDTC) - Net Profitability Margin|Net Sales Margin CRIS (Curis, Inc.)|APLM: Net Return on Sales|Tharimmune Corporation - Net Sales Margin|ADVB: Net Margin|GNPX: Net Sales Margin|CLDI (Calidi Biotherapeutics Inc.) - Net Margin|Net Margin Sunshine Biopharma, Inc.|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)